US CDRH "on track" for user fee goals, guidance ahead
This article was originally published in Clinica
In its quarterly snapshot of agency affairs, FDA officials have disclosed that the device centre (CDRH) remains on track to meet its user fee performance goals for fiscal years 2003 and 2004. Nearly all of the 2003 applications have been closed. Those that remain are the most difficult and challenging submissions, they noted.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.